<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="de">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Dieses Dokument ist eine Zweitveröffentlichung (Verlagsversion)</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2015-06-06">June 6, 2015</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Kurt</forename><surname>Miller</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">University Hospital Charité</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rudolf</forename><surname>Morant</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution">Tumor-und Brustzentrum ZeTuP AG St</orgName>
								<address>
									<settlement>Gallen, St. Gallen</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Arnulf</forename><surname>Stenzl</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">Eberhard-Karls-University Tübingen</orgName>
								<address>
									<settlement>Tübingen</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ivan</forename><surname>Zuna</surname></persName>
							<affiliation key="aff3">
								<address>
									<addrLine>Steinbachweg 37</addrLine>
									<settlement>Heidelberg</settlement>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><roleName>MD</roleName><forename type="first">Manfred</forename><surname>Wirth</surname></persName>
							<email>manfred.wirth@uniklinikum-dresden.de</email>
							<affiliation key="aff4">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">Universität Dresden</orgName>
								<address>
									<settlement>Dresden</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="department">Internationalis Urologia</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff6">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution" key="instit1">University Hospital Carl Gustav Carus</orgName>
								<orgName type="institution" key="instit2">Technical University of Dresden</orgName>
								<address>
									<addrLine>Fetscherstrasse 74</addrLine>
									<postCode>DE-01307</postCode>
									<settlement>Dresden</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Dieses Dokument ist eine Zweitveröffentlichung (Verlagsversion)</title>
					</analytic>
					<monogr>
						<idno type="ISSN">1423-0399</idno>
						<imprint>
							<date type="published" when="2015-06-06">June 6, 2015</date>
						</imprint>
					</monogr>
					<idno type="MD5">B96915ECC6793ED447E9474EB828FC0A</idno>
					<idno type="DOI">10.1159/000381589</idno>
					<note type="submission">Received: October 9, 2014 Accepted after revision: March 10, 2015</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:49+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Cisplatin</term>
					<term>Gefitinib</term>
					<term>Gemcitabine</term>
					<term>Transitional cell carcinoma</term>
					<term>Urothelial carcinoma</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>This is a self-archiving document (published version):</head><p><s>Diese Version ist verfügbar / This version is available on: https://nbn-resolving.org/urn:nbn:de:bsz:14-qucosa2-705898</s><s>"Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFGgeförderten) Allianz-bzw.</s><s>Nationallizenz frei zugänglich."</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="de">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Urothelial carcinoma remains one of the leading causes of cancer mortality and morbidity in Europe <ref type="bibr" target="#b0">[1]</ref> and the United States <ref type="bibr" target="#b1">[2]</ref> .</s><s>Approximately, 20-40% of newly diagnosed patients present with, or go on to develop, invasive disease <ref type="bibr" target="#b2">[3]</ref> .</s><s>Outcomes in these patients are particularly poor, with five-year survival rates for patients presenting with regional or distant metastases of 35 and 5%, respectively <ref type="bibr" target="#b1">[2]</ref> .</s></p><p><s>In other malignancy types, such as non-small cell lung cancer (NSCLC), breast cancer, colorectal cancer, gastrointestinal stromal tumor, and renal cell cancer, the use of targeted therapies has had a major impact in terms of improved outcomes.</s><s>Over the past decade, drugs such as Miller/Morant/Stenzl/Zuna/Wirth Urol Int 2016;96:5-13 DOI: 10.1159/000381589 6 sunitinib, sorafenib, bevacizumab, imatinib, gefitinib, cetuximab, and trastuzumab have contributed to an increased clinical benefit observed in patients with cancer <ref type="bibr">[4]</ref><ref type="bibr" target="#b5">[5]</ref><ref type="bibr" target="#b6">[6]</ref><ref type="bibr" target="#b7">[7]</ref> .</s><s>However, for patients with advanced or metastatic urothelial cancer, there are no approved targeted therapies and chemotherapy remains the standard of care <ref type="bibr" target="#b9">[8]</ref> .</s></p><p><s>The epidermal growth factor receptor (EGFR) has been implicated in the progression of urothelial carcinoma <ref type="bibr" target="#b10">[9]</ref> , and thus can be considered a potential therapeutic target.</s><s>Previous studies report EGFR expression in urothelial carcinoma being in the range of 27 to 91% <ref type="bibr" target="#b11">[10]</ref><ref type="bibr" target="#b12">[11]</ref><ref type="bibr" target="#b13">[12]</ref><ref type="bibr" target="#b14">[13]</ref><ref type="bibr" target="#b15">[14]</ref><ref type="bibr" target="#b16">[15]</ref> .</s><s>Furthermore, EGFR status has been shown to be associated with invasive disease <ref type="bibr" target="#b11">[10]</ref> and predictive of progression and survival <ref type="bibr" target="#b13">[12,</ref><ref type="bibr" target="#b14">13,</ref><ref type="bibr" target="#b17">[16]</ref><ref type="bibr" target="#b18">[17]</ref><ref type="bibr" target="#b19">[18]</ref> .</s></p><p><s>Gefitinib, a selective EGFR tyrosine kinase inhibitor (TKI), has shown activity in preclinical <ref type="bibr" target="#b20">[19]</ref> and clinical <ref type="bibr" target="#b21">[20]</ref> studies in urothelial carcinomas.</s><s>In addition, the combination therapy of gefitinib with gemcitabine and cisplatin has shown activity in other tumors <ref type="bibr" target="#b22">[21]</ref><ref type="bibr" target="#b23">[22]</ref><ref type="bibr" target="#b24">[23]</ref> .</s></p><p><s>The current study was initiated to further investigate the efficacy and safety of concomitant or sequential gefitinib compared with standard chemotherapy alone in chemotherapy-naïve patients with advanced urothelial carcinoma.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients and Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients</head><p><s>Patients eligible for inclusion were ≥ 18 years old, having received no previous chemotherapy or other systemic antitumor therapy, estimated creatinine clearance (COCKCROFT) &lt;60 ml/ min, with histologically or cytologically confirmed, measurable, advanced, or metastatic transitional cell carcinoma of the urothelium and a World Health Organization (WHO) performance status of 0 to 1.</s><s>The study was conducted from December 2003 to October 2008 in accordance with relevant local regulations, the International Conference on Harmonisation Guidelines for Good Clinical Practice, and the ethical principles laid down in the Declaration of Helsinki <ref type="bibr" target="#b25">[24]</ref> .</s><s>All patients provided written informed consent before any study-related procedures were performed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Objectives</head><p><s>The primary objective of the study was to assess the activity of gefitinib (250 mg) in patients with advanced or metastatic transitional cell carcinoma of the urothelium, administered once daily continuously in addition to standard chemotherapy or administered after completion of standard chemotherapy.</s><s>This was measured by time to progression (TTP), based on Response Evaluation Criteria In Solid Tumors (RECIST) v1.0.</s><s>Tumor response assessments were performed by each investigator.</s></p><p><s>The secondary objectives of the study included evaluating the overall response rate (ORR), time to treatment failure (TTF), overall survival (OS), disease control rate (DCR), and duration of re-sponse.</s><s>The safety objective of the study was to measure the safety and tolerability for each treatment arm.</s><s>Serious adverse events (AEs) were defined as an AE that resulted in death; was life-threatening; resulted in hospitalization; resulted in prolonged disability/ incapacity; or a congenital abnormality or birth defect.</s><s>Patients who experienced progression or toxicity were followed up for survival until withdrawal of study medication of the last patient (study closure).</s><s>Patients who withdrew were followed up every 12 weeks for survival information until death.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Design</head><p><s>This was a phase II, multicenter, open-label, randomized study of gemcitabine and cisplatin with or without concomitant or sequential gefitinib.</s><s>Patients were randomized (1: 1:1) into one of three arms.</s><s>Across all three arms, standard chemotherapy was administered in 21-day cycles consisting of gemcitabine 1,250 mg/m 2 on days 1 and 8 and cisplatin 70 mg/m 2 on day 1.</s><s>Arm A received six cycles of gemcitabine and cisplatin plus concomitant gefitinib 250 mg once daily, followed by gefitinib 250 mg once daily as maintenance therapy until tumor progression.</s><s>Arm B received six cycles of gemcitabine and cisplatin followed by gefitinib 250 mg once daily until progression; and arm C received six cycles of gemcitabine and cisplatin followed by observation until progression.</s></p><p><s>An extension group, comprising patients in arm B and arm C who were unable to complete six cycles of chemotherapy either due to toxicity or objective disease progression, received gefitinib 250 mg once daily until further progression.</s><s>Estimating the efficacy and safety profile of patients in the extension arm was a further exploratory endpoint.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical Analysis</head><p><s>For the intent-to-treat (ITT) population, 102 patients (34 per treatment group) were required.</s><s>Assuming a drop-out rate of approximately 20%, the sample size had to be 125 patients.</s><s>The sample size was determined based on the following assumptions: 7.4 months' TTP with gemcitabine and cisplatin alone <ref type="bibr" target="#b26">[25]</ref> , corresponding to an 18-month progression-free rate of 18.5% (exponential survival function); 30% maximum benefit of additional use of gefitinib (sequentially or concomitantly), resulting in a TTP of 9.6 months (27.3% progression-free patients) in the best treatment arm.</s><s>The goal was to have a probability of 75% of concluding that further evaluation of gefitinib plus gemcitabine and cisplatin on the improvement of TTP in patients with advanced or metastatic transitional cell carcinoma of the urothelium is warranted, based on the observed difference in the response rates between the treatment arms using a selection design with three arms <ref type="bibr" target="#b27">[26]</ref> .</s></p><p><s>Standard summary statistics were used to describe variables.</s><s>ORRs and DCRs were summarized with proportions together with exact two-sided 95% confidence intervals (CI).</s><s>Durations (TTP, OS, and duration of response) were summarized using Kaplan-Meier methods.</s><s>The log-rank test was used to assess the differences between treatment arms.</s></p><p><s>Efficacy endpoints were analyzed using the ITT population.</s><s>Safety endpoints were analyzed using the all-subjects-treated (AST) population.</s></p><p><s>Due to the selection design of this study, the trial was noncomparative in the strong confirmatory statistical sense.</s><s>The goal of the study was to select the most efficient of the three treatment arms, Phase II Gemcitabine + Cisplatin +/-Gefitinib Urothelial Cancer Urol Int 2016;96:5-13 DOI: 10.1159/000381589 7 which would be used in a subsequent study.</s><s>Despite the insufficient statistical power to assess trends in patient response to the study treatments, a log-rank test was performed for an exploratory comparison of all three target variables.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Population</head><p><s>A total of 111 patients from 19 research sites in Germany and Switzerland were screened.</s><s>Of these, 105 patients received study treatment (AST population).</s><s>Eighteen of the 105 patients were excluded from the ITT population: three patients as a result of violation of the inclusion/exclusion criteria, and 15 patients as a consequence of missing their tumor assessment.</s><s>Thus, a total of 87 patients were included in the ITT analysis ( fig. <ref type="figure" target="#fig_0">1</ref> ).</s></p><p><s>Disease characteristics at baseline were representative of a population with histologically or cytologically confirmed, measurable, advanced, or metastatic transitional cell carcinoma of the urothelium.</s><s>Two patients who had squamous cell histology were erroneously enrolled.</s><s>The majority had metastatic disease (arm A 90%, arm B 81%, arm C 83%), and a WHO performance status of 0 or 1 ( table <ref type="table" target="#tab_1">1</ref> ).</s><s>Two patients who had a WHO performance status of 2 were incorrectly enrolled.</s><s>Patient demographics were generally consistent across the treatment arms; all patients were of Caucasian origin, and the majority were elderly males.</s><s>Almost all patients had undergone prior surgery, with only four having received prior radiotherapy.</s></p><p><s>The most common surgery performed was transurethral resection of the bladder (41.7%).</s><s>Other operations included cystectomy, nephro-urectomy, prostatectomy, and laparotomy.</s></p><p><s>In total, 19 patients (63.3%) received gefitinib in arm B after completing six cycles of chemotherapy.</s><s>The extension arm included only two patients (1.9%), who were treated with gefitinib; the exploratory analysis was therefore not conducted due to the small sample size.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Efficacy Results</head><p><s>Median TTP for patients in arm A was 6.1 months (95% CI 4.39-9.40), in arm B 6.3 months (95% CI 5.24-7.80),</s><s>and in arm C 7.8 months (95% CI 6. <ref type="bibr">19-9.63</ref>).</s><s>An exploratory analysis indicated that there were no statistically significant differences between the treatment arms ( fig. <ref type="figure" target="#fig_1">2</ref> ).</s></p><p><s>Similarly, there were no significant differences between the treatment arms for any of the secondary endpoints.</s><s>Forty-five of the 87 patients treated with gefitinib had an objective tumor response, according to RECIST criteria, comprising 40 partial responders and five complete responders.</s><s>The ORRs were 58.6, 53.3, and 42.8% in arms A, B, and C, respectively ( table 2 ).</s><s>The median TTF for patients in arms A, B, and C was 5.9 months (95% CI 4.36-9.37),</s><s>5.9 months (95% CI 3.44-7.11),</s><s>and 5.6 months (95% CI 3.54-8.59),</s><s>respectively ( fig. <ref type="figure" target="#fig_2">3</ref> ).</s><s>The median OS for patients in arm A was 13.3 months (95% CI 10.49-19.24), in arm B 8.5 months (95% CI 6.95-14.49),</s><s>and in arm C 15.9 months (95% CI 10.88-31.27)</s><s>( fig. <ref type="figure" target="#fig_3">4</ref> ).</s></p><p><s>Measurements of target and non-target lesions as per RECIST were performed at regular intervals (every two cycles).</s><s>However, the investigator's assessment of the overall response was not collected at each individual time point.</s><s>A statement of the best response achieved during the study was collected at the end of the last chemotherapy visit.</s><s>Thus, the DCR and duration of response were not assessed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Toxicity</head><p><s>All patients treated in the study experienced at least one AE, the most common events being nausea, vomiting, leukopenia, and fatigue.</s><s>Most AEs were characterized by mild-to-moderate intensity (Common Toxicity Criteria (CTC) grades 1 and 2).</s><s>There were 60 serious AEs reported in 105 patients (57.14%,</s><s>AST population), the most frequent being pancytopenia, pyrexia, and vomiting ( table <ref type="table" target="#tab_3">3</ref> ).</s></p><p><s>In arm A, there were 109 AEs considered gefitinibrelated, according to investigator assessment.</s><s>Of these, rash (CTC grade 1 or 2) was the most common (40.0% of patients).</s><s>There were 13 gefitinib-related SAEs in arm A. In arm B, 23 AEs were considered by investigators as likely to be related to gefitinib, of which diarrhea (CTC grade 1 or 2, except in one patient) was the most common (10.8% of patients).</s><s>There were two gefitinib-related SAEs in arm B.</s></p><p><s>Overall, there were 152 cases of therapy delay or dose reduction due to AEs across all arms of the study.</s><s>There were 17 dose interruptions, most frequently due to toxicity.</s><s>There were no dose interruptions in arm C. The most common reason for study discontinuation was death: 10 patients (28.5%) in arm A; 21 patients (56.8%) in arm B; and 17 patients (51.5%) in arm C. In total, there were 61 deaths during the course of the study: 19 (54.3%), 23 (62.2%), and 19 (57.6%) in arms A, B, and C, respectively.</s><s>The most common cause of death was urothelial carcinoma disease progression <ref type="bibr" target="#b18">(17,</ref><ref type="bibr" target="#b21">20,</ref><ref type="bibr" target="#b20">19</ref> in arms A, B, and C, respectively).</s><s>Deaths not considered related to disease progression were caused by septic shock (one patient) and apoplexy (one patient) in arm A, and pulmonary insufficiency (one patient), cardiorespiratory failure (one patient), and unknown cause (one patient) in arm B.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>Cisplatin-based chemotherapy is the standard of care in patients with advanced urothelial carcinoma.</s><s>Specifically, gemcitabine-cisplatin combination chemotherapy has been shown to provide the best efficacy and tolerability, replacing methotrexate, vinblastine, doxorubicin, and cisplatin as the treatment of choice <ref type="bibr" target="#b28">[27]</ref> .</s><s>Efforts to improve outcomes in this patient group have focused on the addition of a third drug.</s><s>It has been proposed that the addition of a targeted therapeutic agent would result in im-  .</s><s>Presently, there are no approved targeted therapies for urothelial carcinoma; however, a number of potential molecular targets are being investigated in clinical research, including the EGFR family, multitargeted TKIs, angiogenesis (vascular endothelial growth factor (VEGF) and VEGFR), fibroblast growth factor receptor (FGFR), RTK-Ras/Raf/MAPK, PI3K/AKT/mTOR, and anti-CTLA4 antibody (reviewed in <ref type="bibr" target="#b29">[28]</ref><ref type="bibr" target="#b30">[29]</ref><ref type="bibr" target="#b31">[30]</ref> ).</s></p><p><s>The aim of the current study was to establish whether the efficacy of the gemcitabine-cisplatin regimen would be improved with the addition of the EGFR-TKI gefitinib.</s><s>This combination and dosing (gefitinib 250 mg, gemcitabine 1,250 mg/m 2 ) appeared to be highly active and well tolerated in a phase I study in patients with advanced solid tumors <ref type="bibr" target="#b22">[21]</ref> .</s><s>The gemcitabine dose of 1,250 mg/m 2 has also been shown to be well tolerated in patients with transitional cell carcinoma of the bladder <ref type="bibr" target="#b32">[31,</ref><ref type="bibr" target="#b33">32]</ref> .</s><s>Our results did not show any significant benefits with either concomitant or sequential gefitinib, although a trend towards higher response rates was observed.</s><s>In our study, the ORRs in both gefitinib arms (arms A and B) were similar to those reported in the gemcitabine-cisplatin only arm (49.4%) in a phase III trial <ref type="bibr" target="#b34">[33]</ref> and slightly higher than those reported in a phase II trial of gemcitabinecisplatin given concomitantly with gefitinib in patients with advanced urothelial carcinoma (58.6 and 53.3% vs. 42.6%)</s><s><ref type="bibr" target="#b35">[34]</ref> .</s><s>Unintentional selection bias may account for the comparatively low response rates.</s><s>It is probable that the OS data were influenced by the nature of subsequent treatments; however, information on these treatments was not collected, and this is therefore recognized as a limitation of the OS findings.</s></p><p><s>The toxicity profiles of both gefitinib arms (arms A and B) were similar to that observed for gemcitabine-cisplatin alone (arm C).</s><s>All AEs were consistent with the</s></p><p><s>a Patients who experienced separate adverse events of different common toxicity criteria grades may have been counted more than once.</s><s>At the time this study was conducted, the role played by mutations in the EGFR gene in the response to gefitinib was not fully understood and EGFR mutation testing was not typically performed in urothelial carcinoma.</s><s>Subsequently, studies in advanced NSCLC have demonstrated that certain somatic EGFR mutations predict for an improved tumor response to gefitinib treatment, compared with wild-type disease.</s><s>Consequently, EGFR mutation testing is now part of routine investigations in advanced NSCLC <ref type="bibr" target="#b36">[35,</ref><ref type="bibr" target="#b37">36]</ref> .</s></p><p><s>A possible explanation for the lack of efficacy observed in the gefitinib arms in comparison with the control arm in the current study could be due to the absence of EGFR mutations conferring sensitivity to EGFR-TKI; however, as retrospective testing is not possible, this cannot be verified.</s><s>In addition, EGFR-TKI-sensitizing mutations in urothelial carcinoma are thought to be extremely rare -a number of studies investigating this tumor type have been unable to determine their existence <ref type="bibr" target="#b38">[37]</ref><ref type="bibr">[38]</ref><ref type="bibr" target="#b41">[39]</ref><ref type="bibr" target="#b42">[40]</ref><ref type="bibr" target="#b43">[41]</ref> .</s><s>Preclinical studies in urothelial carcinoma have found that the tumor cell-growth inhibition effect of gefitinib is independent of both the mutation status and protein level of EGFR <ref type="bibr" target="#b38">[37,</ref><ref type="bibr" target="#b44">42]</ref> .</s><s>Inoue et al. also suggested that upregulation of YY1 and E-cadherin may be implicated in gefitinib-sensitivity observed in certain bladder cancer cell lines <ref type="bibr" target="#b44">[42]</ref> .</s><s>In addition, uncoupling of mitogenic pathways downstream of EGFR, due to PDGFRβ activation, has been shown to cause resistance to gefitinib in bladder cancer cell lines <ref type="bibr" target="#b45">[43]</ref> .</s></p><p><s>Targeting multiple pathways in order to improve treatment outcomes in advanced urothelial cancer has also been suggested.</s><s>Several studies have proposed that co-expression patterns of EGFR alongside other members of the EGFR super-family or the tyrosine kinase recepteur d'origine nantais (RON) may be a better prognostic indicator than any of the receptors alone in urothelial carcinoma <ref type="bibr" target="#b16">[15,</ref><ref type="bibr" target="#b46">44,</ref><ref type="bibr" target="#b47">45]</ref> .</s><s>Hsu et al. have also presented clinical evidence that EGFR and RON are able to activate one another in bladder cancer cell lines <ref type="bibr" target="#b47">[45]</ref> .</s><s>Conflicting results have been reported for the VEGFR and EGFR dual inhibitor vandetanib.</s><s>Greater antitumor activity was exhibited for vandetanib than gefitinib in human bladder cancer cell lines, and vandetanib also displayed synergism with cisplatin <ref type="bibr" target="#b41">[39]</ref> .</s><s>However, vandetanib in combination with docetaxel did not exhibit a significant improvement in progression-free survival in patients with advanced urothelial cancer <ref type="bibr" target="#b48">[46]</ref> .</s></p><p><s>Data indicate that radical treatment of the tumor, even in a metastatic setting, may improve outcomes <ref type="bibr" target="#b49">[47]</ref> , and it would be interesting to investigate whether there were differences in findings between the patients who received transurethral resection, radical cystectomy, and radiation alone.</s><s>Unfortunately, this was not a planned outcome for this study and the data are not available; however, it is recommended that this analysis should be included in future trials of this nature.</s></p><p><s>In summary, gefitinib did not contribute to better patient outcomes in this population of metastatic urothelial carcinoma; platinum-based chemotherapy remains the cornerstone of treatment.</s><s>However, it is hoped that by gaining a better understanding of the different molecular pathways that influence disease progression in this tumor indication, more effective targeted therapies may be developed.</s><s>An assessment of EGFR status would be of potential value in future studies of EGFR/TKIs in urothelial carcinoma; identification of patients that is most likely to benefit from these therapies may also result in improved clinical outcomes.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1 .</head><label>1</label><figDesc><div><p><s>Fig. 1.</s><s>CONSORT diagram.</s><s>a Patients excluded from the ITT analysis as a result of inclusion/exclusion criteria violation (n = 3) and missing tumor assessments (n = 15) -indeterminate across all three arms.</s><s>ITT = Intent-to-treat.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2 .</head><label>2</label><figDesc><div><p><s>Fig. 2. Kaplan-Meier plot of time to progression.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 3 .</head><label>3</label><figDesc><div><p><s>Fig. 3. Kaplan-Meier plot of time to treatment failure.Fig.</s><s>4. Kaplan-Meier plot of overall survival.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Fig. 4 .</head><label>4</label><figDesc><div><p><s>Fig. 3. Kaplan-Meier plot of time to treatment failure.Fig.</s><s>4. Kaplan-Meier plot of overall survival.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Response rates</s></p></div></figDesc><table><row><cell></cell><cell cols="2">Number of patients (%)</cell><cell></cell></row><row><cell></cell><cell>arm A</cell><cell>arm B</cell><cell>arm C</cell></row><row><cell></cell><cell>(n = 29)</cell><cell>(n = 30)</cell><cell>(n = 28)</cell></row><row><cell>ORR</cell><cell>17 (58.6)</cell><cell>16 (53.3)</cell><cell>12 (42.8)</cell></row><row><cell>PR</cell><cell>15 (51.7)</cell><cell>15 (50.0)</cell><cell>10 (35.7)</cell></row><row><cell>CR</cell><cell>2 (6.8)</cell><cell>1 (3.3)</cell><cell>2 (7.1)</cell></row><row><cell>SD</cell><cell>12 (42.8)</cell><cell>10 (35.7)</cell><cell>8 (28.5)</cell></row><row><cell cols="4">CR = Complete response; ORR = overall response rate; PR =</cell></row><row><cell cols="3">partial response; SD = stable disease.</cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Baseline demographics and disease characteristics</s></p></div></figDesc><table><row><cell></cell><cell cols="2">Number of patients (%)</cell><cell></cell></row><row><cell></cell><cell>arm A</cell><cell>arm B</cell><cell>arm C</cell></row><row><cell>Population, n (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="4">All patients screened 36 (100.0) 38 (100.0) 37 (100.0)</cell></row><row><cell>All patients treated</cell><cell>35 (97.2)</cell><cell>37 (97.4)</cell><cell>33 (89.2)</cell></row><row><cell>Intent-to-treat</cell><cell>29 (80.6)</cell><cell>30 (78.9)</cell><cell>28 (75.7)</cell></row><row><cell>Sex, n (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Female</cell><cell>12 (34.3)</cell><cell>12 (32.4)</cell><cell>7 (21.2)</cell></row><row><cell>Male</cell><cell>23 (65.7)</cell><cell>24 (64.9)</cell><cell>26 (78.8)</cell></row><row><cell>Missing</cell><cell>0</cell><cell>1 (2.7)</cell><cell>0</cell></row><row><cell>Age, years</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mean ± SD</cell><cell>61.8±11.3</cell><cell>64.7±9.5</cell><cell>61.4±9.7</cell></row><row><cell>Median</cell><cell>66</cell><cell>66</cell><cell>63</cell></row><row><cell>Range</cell><cell>41-84</cell><cell>45-80</cell><cell>42-78</cell></row><row><cell>Race, n (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Caucasian</cell><cell cols="3">35 (100.0) 37 (100.0) 33 (100.0)</cell></row><row><cell cols="2">WHO performance status</cell><cell></cell><cell></cell></row><row><cell>0</cell><cell>20 (58.8)</cell><cell>17 (45.9)</cell><cell>19 (59.4)</cell></row><row><cell>1</cell><cell>13 (38.2)</cell><cell>19 (51.4)</cell><cell>13 (40.6)</cell></row><row><cell>2</cell><cell>1 (2.9)</cell><cell>1 (2.7)</cell><cell>0</cell></row><row><cell>Missing</cell><cell>1 (2.7)</cell><cell>0 (0.0)</cell><cell>1 (2.7)</cell></row><row><cell>Histology, n (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Transitional cell</cell><cell>28 (80.0)</cell><cell>31 (83.8)</cell><cell>28 (84.9)</cell></row><row><cell>Squamous cell</cell><cell>0</cell><cell>1 (2.7)</cell><cell>1 (3.0)</cell></row><row><cell>Adenoid</cell><cell>2 (5.7)</cell><cell>0</cell><cell>0</cell></row><row><cell>Unknown</cell><cell>4 (11.4)</cell><cell>4 (10.8)</cell><cell>2 (6.1)</cell></row><row><cell>Missing</cell><cell>1 (2.9)</cell><cell>1 (2.7)</cell><cell>2 (6.1)</cell></row><row><cell>Any tumor-related</cell><cell></cell><cell></cell><cell></cell></row><row><cell>surgery</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Yes</cell><cell cols="2">35 (100.0) 34 (91.9)</cell><cell>31 (93.4)</cell></row><row><cell>No</cell><cell>0</cell><cell>3 (8.1)</cell><cell>1 (3.0)</cell></row><row><cell>Missing</cell><cell>0</cell><cell>0</cell><cell>1 (3.0)</cell></row><row><cell cols="2">Any tumor-related radiotherapy</cell><cell></cell><cell></cell></row><row><cell>Yes</cell><cell>0</cell><cell>3 (8.1)</cell><cell>1 (3.0)</cell></row><row><cell>No</cell><cell cols="2">35 (100.0) 33 (89.2)</cell><cell>29 (87.9)</cell></row><row><cell>Missing</cell><cell>0</cell><cell>1 (2.7)</cell><cell>3 (9.1)</cell></row><row><cell cols="4">SD = Standard deviation; WHO = World Health Organization.</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 3 .</head><label>3</label><figDesc><div><p><s>Adverse events and serious adverse events regardless of causality occurring in &gt;10% frequency in any arm</s></p></div></figDesc><table><row><cell>Phase II Gemcitabine + Cisplatin +/-</cell><cell>Urol Int 2016;96:5-13</cell><cell>11</cell></row><row><cell>Gefitinib Urothelial Cancer</cell><cell>DOI: 10.1159/000381589</cell><cell></cell></row></table></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>Medical writing services were provided by Tom Westgate and Kerrie O'Rourke of iMed Comms, Macclesfield, UK, and were funded by AstraZeneca AG, Germany.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Disclosure Statement</head><p><s>The study was funded by AstraZeneca.</s><s>Kurt Miller has received consultancy fees from Amgen, AstraZeneca, Bayer, BMS, Dendreon, Ferring, GSK, Janssen-Cilag, Merck, Novartis, Pfizer, and Roche, and institutional grants from Novartis.</s><s>Rudolf Morant has received consultancy fees for a one-off training session (not related to this manuscript).</s><s>Manfred Wirth has received consultancy fees from Bayer, Dendreon, Janssen-Cilag, Merck, and Takeda Oncology Company -Millennium Pharmaceuticals, and payment for lectures/speakers' bureaus from Janssen-Cilag, Orion Pharma, and Pfizer.</s><s>Ivan Zuna and Arnulf Stenzl have declared no conflicts of interest.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Declining mortality from bladder cancer in Europe</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ferlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Randi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bosetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Levi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Negri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Boyle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">La</forename><surname>Vecchia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BJU Int</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="page" from="11" to="19" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Cancer statistics</title>
		<author>
			<persName><forename type="first">R</forename><surname>Siegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Naishadham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jemal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">CA Cancer J Clin</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="10" to="29" />
			<date type="published" when="2012">2012. 2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Stein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Lieskovsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Cote</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Groshen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Boyd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Skinner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bochner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Thangathurai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mikhail</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Raghavan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Skinner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="666" to="675" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title/>
		<idno type="DOI">10.1159/000381589</idno>
	</analytic>
	<monogr>
		<title level="j">Urol Int</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="5" to="13" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Targeted therapies for cancer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Ross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Schenkein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pietrusko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rolfe</forename><forename type="middle">M</forename><surname>Linette</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">P</forename><surname>Stec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Stagliano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>Ginsburg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Symmans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">F</forename><surname>Pusztai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hortobagyi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">N</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Pathol</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="598" to="609" />
			<date type="published" when="2004">2004. 2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Clinical cancer advances 2009: major research advances in cancer treatment, prevention, and screening -a report from the American society of clinical oncology</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Petrelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Winer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Brahmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dubey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">T</forename><surname>Vahdat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Obel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Vogelzang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Markman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Sweetenham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Pfister</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Kris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Schuchter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sawaya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Raghavan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Ganz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kramer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="6052" to="6069" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">From single-to multitarget drugs in cancer therapy: when aspecificity becomes an advantage</title>
		<author>
			<persName><forename type="first">A</forename><surname>Petrelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Giordano</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Med Chem</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="422" to="432" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Dreyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Raymond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Faivre</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>Targeted therapies and their indications in solid neoplasias</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Rev Med Interne</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="416" to="424" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines</title>
		<author>
			<persName><forename type="first">A</forename><surname>Stenzl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Cowan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Santis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kuczyk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Merseburger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Ribal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Sherif</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Witjes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="1009" to="1018" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases</title>
		<author>
			<persName><forename type="first">M</forename><surname>Gallucci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Merola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Leonardo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Ruggeri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Cianciulli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BJU Int</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="440" to="441" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder</title>
		<author>
			<persName><forename type="first">C</forename><surname>Wright</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mellon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Johnston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Lane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Horne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Neal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="967" to="970" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder</title>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">T</forename><surname>Maclennan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Eble</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lopez-Beltran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">J</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">X</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Montironi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Cheng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="953" to="957" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis</title>
		<author>
			<persName><forename type="first">P</forename><surname>Lipponen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Eskelinen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="1120" to="1125" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Clinical significance of altered nm23-H1, EGFR, RB and p53 expression in bilharzial bladder cancer</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Khaled</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Bahnassy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Raafat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Zekri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Madboul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Mokhtar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Cancer</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">32</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Fine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Epstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Surg Pathol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="883" to="891" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">H</forename><surname>Chow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Tzai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Ho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Liu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="1957" to="1962" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Long-term outcome related to epidermal growth factor receptor status in bladder cancer</title>
		<author>
			<persName><forename type="first">K</forename><surname>Mellon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wright</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kelly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Horne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Neal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Urol</title>
		<imprint>
			<biblScope unit="volume">153</biblScope>
			<biblScope unit="page" from="919" to="925" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome</title>
		<author>
			<persName><forename type="first">C</forename><surname>Kramer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Klasmeyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Bojar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Schulz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ackermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">O</forename><surname>Grimm</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">109</biblScope>
			<biblScope unit="page" from="2016" to="2024" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">H</forename><surname>Chow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">I</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Tzai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Lin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Anticancer Res</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1293" to="1296" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">hEGR1 is induced by EGF, inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Nutt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Foster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Mellon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lunec</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="762" to="768" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Results of the Southwest oncology group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Petrylak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Tangen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Van Veldhuizen</surname></persName>
		</author>
		<author>
			<persName><surname>Jr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Goodwin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename><surname>Twardowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Atkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Kakhil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Lange</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mansukhani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>Crawford</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BJU Int</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="page" from="317" to="321" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors</title>
		<author>
			<persName><forename type="first">G</forename><surname>Giaccone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Gonzalez-Larriba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Van Oosterom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Alfonso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">F</forename><surname>Smit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Martens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Peters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Van Der Vijgh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Averbuch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fandi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="831" to="838" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial -INTACT 1</title>
		<author>
			<persName><forename type="first">G</forename><surname>Giaccone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Herbst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Manegold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Scagliotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Rosell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Natale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Schiller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Von</forename><surname>Pawel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pluzanska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gatzemeier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Grous</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ochs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Averbuch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Wolf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Rennie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Fandi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="777" to="784" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Sirotnak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Zakowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">A</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">I</forename><surname>Scher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Kris</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="4885" to="4892" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title/>
		<ptr target="http://www.wma.net/en/30publications/10policies/b3/" />
	</analytic>
	<monogr>
		<title level="j">World Medical Association</title>
		<imprint>
			<date type="published" when="2008-05-07">2008. accessed May 7, 2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study</title>
		<author>
			<persName><forename type="first">H</forename><surname>Von Der Maase</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Hansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Dogliotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Oliver</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Bodrogi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Albers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Knuth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Lippert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kerbrat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Sanchez Rovira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Wersall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Cleall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Roychowdhury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Tomlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Visseren-Grul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">F</forename><surname>Conte</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="3068" to="3077" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">A flexible design for multiple armed screening trials</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Sargent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Goldberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stat Med</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="1051" to="1060" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Update on chemotherapy for advanced bladder cancer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Rosenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Carroll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Small</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Urol</title>
		<imprint>
			<biblScope unit="volume">174</biblScope>
			<biblScope unit="page" from="14" to="20" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Targeted therapies in non-muscleinvasive bladder cancer according to the signaling pathways</title>
		<author>
			<persName><forename type="first">H</forename><surname>Wallerand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Bernhard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Culine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ballanger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Robert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Reiter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Ferriere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ravaud</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Urol Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="4" to="11" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Carles J: Emerging therapies for urothelial cancer</title>
		<author>
			<persName><forename type="first">C</forename><surname>Serrano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Morales</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Suárez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Núñez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Valverde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rodón</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Humbert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Padrós</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Treat Rev</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="311" to="317" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Urothelial cancers: using biology to improve outcomes</title>
		<author>
			<persName><forename type="first">C</forename><surname>Pezaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Liew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">D</forename><surname>Davis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Rev Anticancer Ther</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="87" to="98" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial</title>
		<author>
			<persName><forename type="first">L</forename><surname>Dogliotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Carteni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Siena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Bertetto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Martoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bono</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Amadori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Onat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Marini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="134" to="141" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Impact of gemcitabine and cisplatin with radiotherapy in locally advanced or metastatic transitional cell carcinoma of urinary bladder</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Mallick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Ali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Siddiqui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fareed</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pak Med Assoc</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="547" to="552" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer</title>
		<author>
			<persName><forename type="first">H</forename><surname>Von Der Maase</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Sengelov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ricci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Dogliotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Oliver</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zimmermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Arning</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="4602" to="4608" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of cancer and leukemia group B (CALGB) 90102</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Philips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Halabi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Sanford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bajorin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Small</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="1074" to="1079" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Lynch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Bell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sordella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gurubhagavatula</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Okimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">W</forename><surname>Brannigan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Haserlat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Supko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">G</forename><surname>Haluska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">N</forename><surname>Louis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Christiani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Settleman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Haber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">350</biblScope>
			<biblScope unit="page" from="2129" to="2139" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Mok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">L</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Thongprasert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Chu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Saijo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Sunpaweravong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Margono</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ichinose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Nishiwaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ohe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Chewaskulyong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Duffield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Watkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Armour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fukuoka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">361</biblScope>
			<biblScope unit="page" from="947" to="957" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-alpha</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">J</forename><surname>Qu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">M</forename><surname>Hayes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Brenner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Russell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Goldstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BJU Int</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="1539" to="1545" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">+/-Gefitinib</forename><surname>Phase Ii Gemcitabine + Cisplatin</surname></persName>
		</author>
		<author>
			<persName><surname>Urothelial</surname></persName>
		</author>
		<idno type="DOI">10.1159/000381589</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer Urol Int</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="5" to="13" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Targeting EGFR in bladder cancer</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Villares</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zigler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Blehm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bogdan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mcconkey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Colin</forename><forename type="middle">D</forename><surname>Bar-Eli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">World J Urol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="573" to="579" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose-and sequence-dependent manner</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Flaig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mccoach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Raben</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Varella-Garcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">T</forename><surname>Bemis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BJU Int</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="page" from="1729" to="1737" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues</title>
		<author>
			<persName><forename type="first">A</forename><surname>Chaux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Schultz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Albadine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jadallah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Schoenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Netto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Pathol</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="1590" to="1595" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Bar-Eli M: Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">N</forename><surname>Blehm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Spiess</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Bondaruk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Dujka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Villares</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">J</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Bogler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Aldape</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">B</forename><surname>Grossman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Adam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Mcconkey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Czerniak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Dinney</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="4671" to="4677" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Gefitinib-related gene signature in bladder cancer cells identified by a cDNA microarray</title>
		<author>
			<persName><forename type="first">R</forename><surname>Inoue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Matsuyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yamamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Iizuka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Naito</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Anticancer Res</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="4195" to="4202" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of gefitinib in bladder cancer cells</title>
		<author>
			<persName><forename type="first">W</forename><surname>Kassouf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Dinney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Mcconkey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Diehl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bar-Eli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Adam</forename><forename type="middle">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="10524" to="10535" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Memon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Sorensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Meldgaard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fokdal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Thykjaer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Nexo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="1703" to="1709" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Collaboration of RON and epidermal growth factor receptor in human bladder carcinogenesis</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">Y</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Tzai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Ho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">H</forename><surname>Chow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Urol</title>
		<imprint>
			<biblScope unit="volume">176</biblScope>
			<biblScope unit="page" from="2262" to="2267" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">A double-blind randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated advanced urothelial cancer</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">K</forename><surname>Choueiri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">N</forename><surname>Vaishampayan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">Y</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">I</forename><surname>Quinn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Hahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Hutson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Ross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Rosenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Jacobus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename><surname>Kantoff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>suppl 7):abstract LBA239</note>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">ICUD-EAU international consultation on bladder cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder</title>
		<author>
			<persName><forename type="first">G</forename><surname>Gakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Efstathiou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Lerner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Cookson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Keegan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Guru</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">U</forename><surname>Shipley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Heidenreich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Schoenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">I</forename><surname>Sagaloswky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Soloway</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Stenzl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="45" to="57" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
